FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:986-987 October 1, 1998 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Glorieux, F. H. PubMed Citation

Osteogenesis imperfecta is an autosomal dominant disorder of the connective tissue, which is also known as "brittle-bone disease" because it renders those affected susceptible to fractures after minimal trauma. Clinically and biochemically, osteogenesis imperfecta is a generalized disorder of the connective tissue, characterized by various combinations of blue sclerae, triangular facies, macrocephaly, hearing loss, defective dentition, barrel chest, vertebral compression and scoliosis, progressive limb deformity and bowing, joint laxity, and varying degrees of growth retardation.

The currently accepted classification of the disease includes four types defined according to clinical and radiographic features, with some overlap among them.¹ Type I is . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Falk, M. J., Heeger, S., Lynch, K. A., DeCaro, K. R., Bohach, D., Gibson, K. S., Warman, M. L. (2003). Intravenous Bisphosphonate Therapy in Children With Osteogenesis Imperfecta. Pediatrics 111: 573-578 [Abstract] [Full Text]  
• Banerjee, I, Shortland, G J, Evans, W D, Gregory, J W (2002). Osteogenesis imperfecta and intravenous pamidronate. Arch. Dis. Child. 87: 562-563 [Full Text]  
• , (2001). Severe osteogenesis imperfecta: new therapeutic. BMJ 322: 63-64 [Full Text]